Gestational trophoblastic disease: The significance of vaginal metastases

Gary L. Goldberg, Denzil A. Yon, Basil Bloch, Wilfred Levin

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Five patients with gestational trophoblastic disease whose presenting symptom was hemorrhage from vaginal metastases have been added to our previous report. The clinical features, management, and responses to treatment are outlined. All the patients required suturing of the bleeding lesions under general anesthetic to arrest the hemorrhage. In addition one patient needed selective arterial embolization. This did not compromise the response to chemotherapy. We confirm our previous view that the presence of vaginal metastases should be classified as a high-risk factor and that these patients be treated with multiple agent chemotherapy from the outset.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalGynecologic Oncology
Volume24
Issue number2
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Gestational Trophoblastic Disease
Neoplasm Metastasis
Hemorrhage
Drug Therapy
General Anesthetics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Gestational trophoblastic disease : The significance of vaginal metastases. / Goldberg, Gary L.; Yon, Denzil A.; Bloch, Basil; Levin, Wilfred.

In: Gynecologic Oncology, Vol. 24, No. 2, 1986, p. 155-161.

Research output: Contribution to journalArticle

Goldberg, Gary L. ; Yon, Denzil A. ; Bloch, Basil ; Levin, Wilfred. / Gestational trophoblastic disease : The significance of vaginal metastases. In: Gynecologic Oncology. 1986 ; Vol. 24, No. 2. pp. 155-161.
@article{8e2735f452ab4bc596ce3d71eedd9e56,
title = "Gestational trophoblastic disease: The significance of vaginal metastases",
abstract = "Five patients with gestational trophoblastic disease whose presenting symptom was hemorrhage from vaginal metastases have been added to our previous report. The clinical features, management, and responses to treatment are outlined. All the patients required suturing of the bleeding lesions under general anesthetic to arrest the hemorrhage. In addition one patient needed selective arterial embolization. This did not compromise the response to chemotherapy. We confirm our previous view that the presence of vaginal metastases should be classified as a high-risk factor and that these patients be treated with multiple agent chemotherapy from the outset.",
author = "Goldberg, {Gary L.} and Yon, {Denzil A.} and Basil Bloch and Wilfred Levin",
year = "1986",
doi = "10.1016/0090-8258(86)90022-3",
language = "English (US)",
volume = "24",
pages = "155--161",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Gestational trophoblastic disease

T2 - The significance of vaginal metastases

AU - Goldberg, Gary L.

AU - Yon, Denzil A.

AU - Bloch, Basil

AU - Levin, Wilfred

PY - 1986

Y1 - 1986

N2 - Five patients with gestational trophoblastic disease whose presenting symptom was hemorrhage from vaginal metastases have been added to our previous report. The clinical features, management, and responses to treatment are outlined. All the patients required suturing of the bleeding lesions under general anesthetic to arrest the hemorrhage. In addition one patient needed selective arterial embolization. This did not compromise the response to chemotherapy. We confirm our previous view that the presence of vaginal metastases should be classified as a high-risk factor and that these patients be treated with multiple agent chemotherapy from the outset.

AB - Five patients with gestational trophoblastic disease whose presenting symptom was hemorrhage from vaginal metastases have been added to our previous report. The clinical features, management, and responses to treatment are outlined. All the patients required suturing of the bleeding lesions under general anesthetic to arrest the hemorrhage. In addition one patient needed selective arterial embolization. This did not compromise the response to chemotherapy. We confirm our previous view that the presence of vaginal metastases should be classified as a high-risk factor and that these patients be treated with multiple agent chemotherapy from the outset.

UR - http://www.scopus.com/inward/record.url?scp=0022443676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022443676&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(86)90022-3

DO - 10.1016/0090-8258(86)90022-3

M3 - Article

C2 - 3011614

AN - SCOPUS:0022443676

VL - 24

SP - 155

EP - 161

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -